Furthermore, STAT5 activity is associated with poor prognosis in CML and its deletion in BCR-ABL1++ cells induces apoptosis, even in cells which have developed resistance to tyrosine kinase inhibitors (TKI) (Ren, 2005). The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.